REDUCER Trial (TXA in Urethroplasty)

Starting soon · Phase 4

Conditions studied: Urethral Stricture, Urethral Diseases

In brief

This study will test whether tranexamic acid (TXA), a medication used to reduce bleeding, can decrease blood loss in patients having urethroplasty. Participants will be randomly assigned to receive either a single intravenous dose of TXA at the start of anesthesia or standard care without TXA. Researchers will compare hemoglobin change after surgery as well as estimated blood loss and complications.

Key facts

Study ID

NCT07501884

Run by

Amjad Alwaal, MD, MSc, FRCSC, FACS

People needed

40

Starts

2026-05-01

Expected to finish

2027-03-30

Last updated by the study team

2026-03-30

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Adult patients (≥18 years old)
• Undergoing urethroplasty for urethral stricture disease
• Ability to provide informed consent

You may not qualify if…

• Known contraindication to tranexamic acid (TXA)
• History of thromboembolic disease (e.g., deep vein thrombosis, pulmonary embolism, stroke)
• Known bleeding disorder or coagulopathy
• Current use of anticoagulation that cannot be safely held perioperatively
• Severe renal impairment
• Allergy or hypersensitivity to tranexamic acid
• History of seizures
• Inability to provide informed consent

Where it is running

• University Hospital — Newark, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.